JP2013536233A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536233A5
JP2013536233A5 JP2013526063A JP2013526063A JP2013536233A5 JP 2013536233 A5 JP2013536233 A5 JP 2013536233A5 JP 2013526063 A JP2013526063 A JP 2013526063A JP 2013526063 A JP2013526063 A JP 2013526063A JP 2013536233 A5 JP2013536233 A5 JP 2013536233A5
Authority
JP
Japan
Prior art keywords
piperazinyl
phenyl
methyl
trifluoro
propanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013526063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536233A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/048596 external-priority patent/WO2012027261A1/en
Publication of JP2013536233A publication Critical patent/JP2013536233A/ja
Publication of JP2013536233A5 publication Critical patent/JP2013536233A5/ja
Pending legal-status Critical Current

Links

JP2013526063A 2010-08-23 2011-08-22 グルコキナーゼ調節タンパク質と相互作用する糖尿病治療用の化合物 Pending JP2013536233A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37614110P 2010-08-23 2010-08-23
US61/376,141 2010-08-23
US201161492634P 2011-06-02 2011-06-02
US61/492,634 2011-06-02
PCT/US2011/048596 WO2012027261A1 (en) 2010-08-23 2011-08-22 Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes

Publications (2)

Publication Number Publication Date
JP2013536233A JP2013536233A (ja) 2013-09-19
JP2013536233A5 true JP2013536233A5 (enExample) 2014-05-15

Family

ID=44840531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013526063A Pending JP2013536233A (ja) 2010-08-23 2011-08-22 グルコキナーゼ調節タンパク質と相互作用する糖尿病治療用の化合物

Country Status (10)

Country Link
US (1) US8431563B2 (enExample)
EP (1) EP2609081A1 (enExample)
JP (1) JP2013536233A (enExample)
AR (1) AR082534A1 (enExample)
AU (1) AU2011293584B2 (enExample)
CA (1) CA2808590A1 (enExample)
MX (1) MX2013002208A (enExample)
TW (1) TW201238941A (enExample)
UY (1) UY33568A (enExample)
WO (1) WO2012027261A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123444A1 (en) * 2012-02-17 2013-08-22 Amgen Inc. Sulfonyl compounds that interact with glucokinase regulatory protein
WO2013173382A1 (en) * 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
WO2014035872A1 (en) * 2012-08-27 2014-03-06 Amgen Inc. Tricyclic alkynes that interact with glucokinase regulatory protein
JP6102637B2 (ja) * 2013-08-22 2017-03-29 Jsr株式会社 芳香族ジハライド化合物、重合体、重合体組成物及び成形体
CN108912020B (zh) * 2018-06-05 2021-05-28 上海博志研新药物技术有限公司 奥当卡替及其中间体的制备方法
WO2021072369A1 (en) * 2019-10-11 2021-04-15 Duke University Lpxh targeting compounds, compositions thereof, and methods of making and using the same
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种(R)-1-Boc-3-羟甲基哌嗪的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9821199D0 (en) 1998-09-30 1998-11-25 Glaxo Group Ltd Chemical compounds
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-il-1r1 모노클로날 항체
ATE551997T1 (de) * 2003-09-12 2012-04-15 Merck Serono Sa Sulfonamid-derivate zur behandlung von diabetes
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
GB0505084D0 (en) 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
AU2006279312A1 (en) 2005-08-19 2007-02-22 Elan Pharmaceuticals, Inc. Bridged N-cyclic sulfonamido inhibitors of gamma secretase
US7825122B2 (en) * 2005-12-14 2010-11-02 Amgen Inc. Diaza heterocyclic sulfonamide derivatives and their uses
US7524848B2 (en) * 2006-03-23 2009-04-28 Amgen Inc. Diaza heterocyclic amide compounds and their uses
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EP2573087A1 (en) 2007-09-21 2013-03-27 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2009096198A1 (ja) * 2008-02-01 2009-08-06 Pharma Ip Limited Liability Intermediary Corporations 新規ビアリール誘導体
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
FR2935380B1 (fr) 2008-08-29 2010-09-10 Galderma Res & Dev Nouveaux composes hexafluoro-2-biphenyl-isopropanol, modulateurs des recepteurs de type lxrs, leur procede de preparation et leur application comme medicaments en medecine humaine ou veterinaire ainsi qu'en cosmetique.
MY148558A (en) 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof

Similar Documents

Publication Publication Date Title
JP2013536233A5 (enExample)
US11905283B2 (en) Compounds and compositions for inhibiting the activity of SHP2
US11591336B2 (en) Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
ES2649144T3 (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina D1
US20220089597A1 (en) Compounds and compositions for inhbiting the activity of shp2
US20250018049A1 (en) Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
JP2007509141A5 (enExample)
JP2025535046A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
JP2020531498A5 (enExample)
CN103261202B (zh) 作为腺苷受体拮抗剂的稠合三环化合物
JP2012522748A5 (enExample)
CN101263130A (zh) 2-苯胺-4-芳基取代的噻唑衍生物
JP2017524028A (ja) 薬剤としてのrip1キナーゼ阻害剤である複素環式アミド
JP2018135350A (ja) 炎症性障害の治療のための化合物及びその医薬組成物
CN103096718A (zh) 可溶性鸟苷酸环化酶活化剂
US10072003B2 (en) Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use
KR20080040681A (ko) 아데노신 수용체 길항제로서 유용한 피라진 유도체
US20140200344A1 (en) Tricyclic heterocyclic compounds and jak inhibitors
JP2007529484A5 (enExample)
JP6893516B2 (ja) 3−((ヘテロ−)アリール)−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
TW201321353A (zh) 胺基甲酸酯/尿素衍生物
JP2017523223A5 (enExample)
US12331026B2 (en) Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
CN120500475A (zh) 包括金属通道激活剂的组合疗法
EA034904B1 (ru) Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро-[4.5]-декана